Ifosfamide and Epirubicin Combination in Untreated Sarcomas: Two Treatment Schedules

2001 ◽  
Vol 24 (5) ◽  
pp. 465-468 ◽  
Author(s):  
L. Serrone ◽  
M. Zeuli ◽  
P. Papaldo ◽  
C. Nardoni ◽  
U. Pacetti ◽  
...  
Keyword(s):  
Epirubicin Combination

Carboplatin and epirubicin combination therapy for advanced malignant epithelial skin tumors: Retrospective study of six patients

2018 ◽  
Vol 45 (7) ◽  
pp. 874-875 ◽  
Author(s):  
Yoshio Nakamura ◽  
Keiji Tanese ◽  
Ikuko Hirai ◽  
Yutaka Kawakami ◽  
Takeru Funakoshi
Keyword(s):  
Retrospective Study ◽  
Combination Therapy ◽  
Skin Tumors ◽  
Epirubicin Combination

A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma

Lung Cancer ◽  
2005 ◽  
Vol 50 (1) ◽  
pp. 75-82 ◽  
Author(s):  
T. Berghmans ◽  
J.J. Lafitte ◽  
M. Paesmans ◽  
B. Stach ◽  
M.C. Berchier ◽  
...  
Keyword(s):  
Phase Ii ◽  
Malignant Pleural Mesothelioma ◽  
Phase Ii Study ◽  
Pleural Mesothelioma ◽  
Epirubicin Combination

A Phase II Study of Cisplatin, Ifosfamide and Epirubicin Combination Chemotherapy in Adults with Nonmetastatic and Extremity Osteosarcomas

Oncology ◽  
2007 ◽  
Vol 72 (3-4) ◽  
pp. 255-260 ◽  
Author(s):  
Mert Basaran ◽  
E. Sevil Bavbek ◽  
Sezer Saglam ◽  
Levent Eralp ◽  
Burak Sakar ◽  
...  
Keyword(s):  
Phase Ii ◽  
Combination Chemotherapy ◽  
Phase Ii Study ◽  
Epirubicin Combination

scholarly journals A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS)

Sarcoma ◽  
2004 ◽  
Vol 8 (4) ◽  
pp. 129-133 ◽  
Author(s):  
Haralabos P. Kalofonos ◽  
Charalabos Kourousis ◽  
Michalis V. Karamouzis ◽  
Gregoris Iconomou ◽  
Ekaterini Tsiata ◽  
...  
Keyword(s):  
Response Rate ◽  
Phase Ii Study ◽  
Locally Advanced ◽  
Soft Tissue Sarcomas ◽  
Complete Response ◽  
Efficacy And Safety ◽  
First Line ◽  
Grade 3 ◽  
Epirubicin Combination ◽  
Line Chemotherapy

Purpose:The aim of this study was to determine the efficacy and safety of docetaxel plus epirubicin combination as first-line chemotherapy in patients with locally advanced and/or metastatic adult STS.Patients and Methods:Eighteen patients were treated with epirubicin 30 mg/m2on days 1 to 3 and docetaxel 100 mg/m2on day 1 every 3 weeks.Results:Fifteen out of 18 patients (83.4%) were assessable for response. No complete response was recorded. Three (20%) patients achieved PR, 3 had SD and 9 PD. The overall median survival was 14 months (range, 3–48 months) and the median time to disease progression was 4 months (range, 2–45 months). Grade ≥ 3 neutropenia occurred in 88% and neutropenic fever in 27.8% of patients. Other toxicities were mild. No treatment related deaths occurred.Discussion:Docetaxel plus epirubicin combination achieved low response rate with severe myelotoxicity in patients with advanced STS.

A case report of primary osteosarcoma of the ovary

2006 ◽  
Vol 16 (Suppl 1) ◽  
pp. 349-352 ◽  
Author(s):  
V. Vyas ◽  
A. M.A. Rammah ◽  
S. D. Ashebu ◽  
G. M. Sharaan ◽  
M. El-Sayed ◽  
...  
Keyword(s):  
Small Bowel ◽  
Progressive Disease ◽  
Bowel Resection ◽  
Exploratory Laparotomy ◽  
Small Bowel Resection ◽  
Ovarian Mass ◽  
Review Of The Literature ◽  
Primary Osteosarcoma ◽  
Subacute Intestinal Obstruction ◽  
Epirubicin Combination

Primary osteosarcoma is one of the rare tumors affecting ovaries. This case is being reported for its rarity, along with a review of the literature. In this study, the patient, a 43-year-old woman, presented with an abdominopelvic mass. Exploratory laparotomy was performed, which revealed an extensive left ovarian mass infiltrating the uterus, small bowel, and urinary bladder. Subtotal hysterectomy and small bowel resection followed by end-to-end anastomosis and bilateral salpingo-ophorectomy were performed. Histopathology showed primary osteosarcoma of the ovary. Eighteen days after surgery, she started presenting with progressive abdominal distention and ultimately developed subacute intestinal obstruction. She was started on carboplatin and epirubicin combination but failed to respond and died of fast progressive disease. It is concluded that primary osteosarcoma of the ovary is a rare disease with poor prognosis.

Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer

2001 ◽  
Vol 70 (3) ◽  
pp. 185-195 ◽  
Author(s):  
Mario Airoldi ◽  
Luigi Cattel ◽  
Fulvia Pedani ◽  
Sara Marchionatti ◽  
Valentina Tagini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Pharmacokinetic Data ◽  
Epirubicin Combination

Efficacy and tolerability of the ifosfamide-epirubicin combination in relapsed ovarian cancer

2006 ◽  
Vol 16 (1) ◽  
pp. 77-82 ◽  
Author(s):  
F. JOLY ◽  
H. BOURGEOIS ◽  
A. FLOQUET ◽  
P. CHINET-CHARROT ◽  
F. MEYER ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epirubicin Combination
Sign in / Sign up

Export Citation Format

Share Document